Entresto 24 mg/26 mg film-coated tablets

DRUG4 trials

Sponsors

Ziekenhuis Oost Limburg, Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda, Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy, Uniwersytecki Szpital Kliniczny W Poznaniu

Conditions

Heart Failure with reduced ejection fraction.Heart failure with preserved ejection fraction Secundary mitral valve regurgitationTransthyretin cardiac amyloidosisarrhythmogenic in the old space of cardiomyopathy

Phase 3

Sacubitril/valsartan in the prevention of disease progression in patients with an ancient arrhythmogenic service - ARNI-ARVC multicentre randomized trial

RecruitingCTIS2024-517412-29-00

Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczyarrhythmogenic in the old space of cardiomyopathy

Start: 2023-07-10Target: 120Updated: 2025-05-09

Phase 4

Sacubitril-Valsartan in Heart Failure with Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation (PRAISE-MR)

Active, not recruitingCTIS2023-506634-70-00

Ziekenhuis Oost LimburgHeart failure with preserved ejection fraction Secundary mitral valve regurgitation

Start: 2024-02-29Target: 110Updated: 2023-10-11

Effect of pharmacological treatment with angiotensin receptor/neprilysin inhibitors on transthyretin cardiac amyloidosis and heart failure with reduced ejection fraction (SAVA-TTR trial)

RecruitingCTIS2024-515661-34-00

Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro MajadahondaTransthyretin cardiac amyloidosis

Start: 2025-02-27Target: 114Updated: 2024-10-24

Pulmonary REsistance modification under treatment with Sacubitil/valsartaN in paTients with HeartFailure with reduced ejection fraction

CompletedCTIS2024-517975-19-00

Uniwersytecki Szpital Kliniczny W PoznaniuHeart Failure with reduced ejection fraction.

Start: 2022-12-12End: 2025-07-18Target: 32Updated: 2024-12-18